Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L5WM
|
|||
| Former ID |
DAP000496
|
|||
| Drug Name |
Amiodarone
|
|||
| Synonyms |
Amidorone; Aminodarone; Amiobeta; Amiodarex; Amiodarona; Amiodarons; Amiodaronum; Amiohexal; Amjodaronum; Ancar; Aratac;Arycor; Braxan; Corbionax; Cordarex; Cordarone; Kordaron; Labaz; Ortacrone; Pacerone; Rytmarone; Sedacoron; Sedacorone; Tachydaron; ASTA Medica Brand of Amiodarone Hydrochloride; Alphapharm Brand of Amiodarone Hydrochloride; Amiodarone Base; Armstrong Brand of Amiodarone Hydrochloride; Berenguer Infale Brand of Amiodarone Hydrochloride; Betapharm Brand of Amiodarone Hydrochloride; Cordarone Intravenous; G Gam Brand of Amiodarone Hydrochloride; Hexal Brand of Amiodarone Hydrochloride; Leurquin Brand of Amiodarone Hydrochloride; Pharma Investi Brand of Amiodarone Hydrochloride; Sanofi Winthrop Brand of Amiodarone Hydrochloride; Wyeth Brand of Amiodarone Hydrochloride; Ethylaminoethoxy)benzoyl]benzofuran; L 3428; L3428; SKF 33134A; Amio-Aqueous IV; Amiodarona [INN-Spanish]; Amiodaronum [INN-Latin]; Aratac (TN); Arycor (TN); Atlansil (TN); Cordarone (TN); L-3428; Pacerone (TN); Pms-Amiodarone; SKF 33134-A; Amiodarone (USAN/INN); Amiodarone [USAN:BAN:INN]; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); (2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; 2-Butyl-3-[3,5-diiodo-4-(2-di; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Tachyarrhythmias [ICD-11: BC71; ICD-10: I49, I49.8] | Approved | [1], [2] | |
| Therapeutic Class |
Antiarrhythmic Agents
|
|||
| Company |
Wyeth-Ayerst Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H29I2NO3
|
|||
| Canonical SMILES |
CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
|
|||
| InChI |
1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
|
|||
| InChIKey |
IYIKLHRQXLHMJQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1951-25-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9041, 650805, 4266412, 5487933, 7978689, 8145887, 8151466, 11110784, 11110785, 11119907, 11120395, 11120883, 11121639, 11122119, 11146990, 11335254, 11360493, 11362708, 11363155, 11365270, 11365717, 11367832, 11368279, 11370687, 11370688, 11371900, 11373433, 11374997, 11375994, 11376441, 11446237, 11461465, 11466437, 11467557, 11485561, 11486013, 11489629, 11490865, 11493004, 11494075, 14765719, 17397067, 24424556, 26751596, 26751597, 29221336, 46507387, 46519007, 47216511, 47364902
|
|||
| ChEBI ID |
CHEBI:2663
|
|||
| ADReCS Drug ID | BADD_D00115 ; BADD_D00116 | |||
| SuperDrug ATC ID |
C01BD01
|
|||
| SuperDrug CAS ID |
cas=001951253
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli Nissle 1917
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Resulting Metabolite | Desethylamiodarone | |||
| Metabolic Effect | Increase activity | |||
| Description | Amiodarone can be metabolized to Desethylamiodarone by Escherichia coli Nissle 1917, which results in the increase of the drug's activity. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3], [4] | |||
| Metabolic Reaction | N-dealkylation | |||
| Metabolic Effect | Increase activity | |||
| Description | Amiodarone can be metabolized by gut microbiota through N-dealkylation, which results in the increase of the drug's activity. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Amiodarone hydrochloride (adjusted p-values: 2.90E-03). | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Amiodarone hydrochloride (adjusted p-values: 8.68E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bifidobacterium longum was decreased by Amiodarone hydrochloride (adjusted p-values: 4.14E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Amiodarone hydrochloride (adjusted p-values: 1.13E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Amiodarone hydrochloride (adjusted p-values: 1.58E-05). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Amiodarone hydrochloride (adjusted p-values: 7.04E-05). | |||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Amiodarone hydrochloride (adjusted p-values: 1.47E-04). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Amiodarone hydrochloride (adjusted p-values: 1.26E-03). | |||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Amiodarone hydrochloride (adjusted p-values: 1.30E-04). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Amiodarone hydrochloride (adjusted p-values: 2.57E-04). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Potassium channel unspecific (KC) | Target Info | Modulator | [6] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2566). | |||
| REF 2 | New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. | |||
| REF 3 | Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev. 2018 Aug;50(3):357-368. | |||
| REF 4 | Predicting and Understanding the Human Microbiome's Impact on Pharmacology. Trends Pharmacol Sci. 2019 Jul;40(7):495-505. | |||
| REF 5 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.